These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8843189)

  • 1. Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia.
    Otto C; Ritter MM; Soennichsen AC; Schwandt P; Richter WO
    Metabolism; 1996 Oct; 45(10):1305-11. PubMed ID: 8843189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
    Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
    J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
    Koh KK; Quon MJ; Shin KC; Lim S; Lee Y; Sakuma I; Lee K; Han SH; Shin EK
    Atherosclerosis; 2012 Feb; 220(2):537-44. PubMed ID: 22153696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia.
    Otto C; Pschierer V; Soennichsen AC; Schwandt P; Richter WO
    Metabolism; 1997 Nov; 46(11):1299-304. PubMed ID: 9361689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
    Tremblay AJ; Lamarche B; Ruel IL; Hogue JC; Deshaies Y; Gagné C; Couture P
    Atherosclerosis; 2006 Sep; 188(1):203-12. PubMed ID: 16337207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III.
    Lussier-Cacan S; Bard JM; Boulet L; Nestruck AC; Grothé AM; Fruchart JC; Davignon J
    Atherosclerosis; 1989 Aug; 78(2-3):167-82. PubMed ID: 2783201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
    J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
    Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
    Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
    Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
    Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.
    Koh KK; Oh PC; Sakuma I; Lee Y; Han SH; Shin EK
    Int J Cardiol; 2016 Oct; 221():342-6. PubMed ID: 27424313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia.
    Oh PC; Koh KK; Sakuma I; Lim S; Lee Y; Lee S; Lee K; Han SH; Shin EK
    Int J Cardiol; 2014 Oct; 176(3):696-702. PubMed ID: 25147070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.
    Bragt MC; Mensink RP
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):966-73. PubMed ID: 21429719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hypertriglyceridemia with fenofibrate, fatty acid composition of plasma and LDL, and their relations to parameters of lipoperoxidation of LDL.
    Zeman M; Zák A; Vecka M; Tvrzická E; Romaniv S; Konárková M
    Ann N Y Acad Sci; 2002 Jun; 967():336-41. PubMed ID: 12079861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
    Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
    Rosenson RS; Huskin AL; Wolff DA; Helenowski IB; Rademaker AW
    Atherosclerosis; 2008 Jun; 198(2):381-8. PubMed ID: 18242616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease.
    Camacho-Muñoz D; Kiezel-Tsugunova M; Kiss O; Uddin M; Sundén M; Ryaboshapkina M; Lind L; Oscarsson J; Nicolaou A
    FASEB J; 2021 Nov; 35(11):e21976. PubMed ID: 34618982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.